M
MacuLogix
Advanced dark adaptometers for early AMD detection, enhancing patient outcomes with AI-driven precision and clinical reliability
About MacuLogix
MacuLogix operates in the healthcare technology market, specializing in devices that aid in the early detection of age-related macular degeneration (AMD). The company's flagship product, the AdaptDx Pro, is a high-tech dark adaptometer that helps eye care professionals identify AMD in its early stages. The device is powered by artificial intelligence, featuring an on-board technician named Theia, who guides patients through the testing process to ensure consistent and reliable results. MacuLogix serves eye care professionals and practices, providing them with tools to improve patient outcomes through early diagnosis and monitoring of AMD. The business model revolves around selling these advanced diagnostic devices and offering training and support through the AMD Academy, a community platform for continuous learning and professional development. Revenue is generated through the sale of the AdaptDx Pro devices and associated training services.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2004
- Headquarters
- Hummelstown, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 69.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Health Diagnostics, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Mar 2019 | $39M | $155M | Life Sciences Greenhouse Investments · Berwind Private Equity · Roche Venture Fund · Vivo Capital | — |
| DEBTDebt | Jul 2018 | $10M | — | Horizon Technology Finance Corporation · Silicon Valley Bank | — |
Growth signals
Latest recorded traffic for MacuLogix is 630 monthly website visits, up 57.5% over the last three months. MacuLogix's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Roche Venture Fund
Life Sciences Greenhouse Investments
Berwind Private Equity
Series B and later3 investors entered at this stage
Horizon Technology Finance Corporation
Silicon Valley Bank
Vivo Capital
Other known investors1 additional known investor
The University of Alabama at Birmingham
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about MacuLogix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MacuLogix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.